- Conditions
- Lung Diseases, Pulmonary Embolism
- Interventions
- Magnetic Resonance Angiography, Magnetic Resonance Venography
- Procedure
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Rockville, Maryland + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 268
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure
- Interventions
- Spironolactone 100mg, Spironolactone 25mg
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- Tocilizumab, Intravenous Immunoglobulin
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic, Silent Stroke, Silent Cerebral Infarct, Stroke
- Interventions
- Hydroxyurea therapy per standard care
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 16 Years to 26 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Major Depressive Disorder
- Interventions
- Tocilizumab, Placebo, Whole-Body Hyperthermia
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab [RoActemra/Actemra], Placebo, Methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 57 more
- Conditions
- Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia
- Interventions
- tocilizumab-aazg (TYENNE)
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Intermediate Uveitis, Posterior Uveitis, Pan-uveitis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Feraheme MRI/MRA
- Procedure
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- COVID-19
- Interventions
- Tocilizumab, Placebo
- Drug
- Lead sponsor
- Queen's Medical Center
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Hemophagocytic Lymphohistiocytosis
- Interventions
- tocilizumab
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 3 Months to 25 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood
- Interventions
- Tocilizumab, CART 19
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 1 Year to 24 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg)
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab, Ortho-Novum® 1/35
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more
- Conditions
- Living-Donor Kidney Transplant, Kidney Transplant Recipients
- Interventions
- lulizumab pegol, antithymocyte globulin (rabbit), methylprednisolone, tocilizumab, Prednisone, everolimus, belatacept, mycophenolate mofetil, mycophenolic acid
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 4 more
- Conditions
- Hemodialysis Access Failure
- Interventions
- The three-dimensional (3D) printed hemodialysis vascular model
- Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Castleman's Disease
- Interventions
- tocilizumab [RoActemra/Actemra]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Worcester, Massachusetts • Duncansville, Pennsylvania
- Conditions
- Advanced Liver Cancers
- Interventions
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 16
- States / cities
- Costa Mesa, California • Duarte, California • Orange, California + 11 more
- Conditions
- Healthy Volunteer
- Interventions
- AI-1000 G2, PFS-NSD, Tocilizumab
- Device · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Lenexa, Kansas • Marlton, New Jersey • Salt Lake City, Utah
- Conditions
- Coronary Artery Disease
- Interventions
- Coronary MR Angiography (CMRA)
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Shoulder Pain
- Interventions
- Indirect MRA of shoulder, Gadopentetate Dimeglumine
- Procedure · Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- SARS-CoV 2
- Interventions
- Tocilizumab, Placebos
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Newton, Massachusetts